U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets
U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets

U.S. FDA approved Lupin's Divalproex Sodium Extended-Release (ER) Tablets

DSIJ Intelligence Article rating: 5.0

Lupin Limited received approval for its Divalproex Sodium Extended-Release (ER) Tablets USP, 250 mg and 500 mg, from the United States Food and Drug Administration (U.S. FDA), to market a generic equivalent of Depakote Extended-Release Tablets, 250 mg and 500 mg, of AbbVie Inc.

Larsen & Toubro awarded by a mega EPCC project
Larsen & Toubro awarded by a mega EPCC project

Larsen & Toubro awarded by a mega EPCC project

DSIJ Intelligence Article rating: 4.0

Larsen and Toubro Hydrocarbon Engineering Limited (LTHE) on Wednesday, has been awarded a mega EPCC project by Hindustan Petroleum Corporation Limited (HPCL). LTHE is a wholly owned subsidiary of Larsen and Toubro.

Market ends in green after a volatile session
Market ends in green after a volatile session

Market ends in green after a volatile session

Nidhi Jani Article rating: 5.0

The BSE Sensex ended at 39058.83, up by 94.99 points or 0.24%. The broader indices ended mixed; the BSE Mid cap index fell 0.18%, while Small cap index was up by 0.24%.

Jubilant Life Sciences gains 4 per cent at closing hours
Jubilant Life Sciences gains 4 per cent at closing hours

Jubilant Life Sciences gains 4 per cent at closing hours

DSIJ Intelligence Article rating: 5.0

Jubilant Life Sciences’ material wholly owned subsidiary Jubilant Pharma through one of its wholly owned subsidiaries has received Abbreviated New Drug Application (ANDA) final approval

 


The catch behind No-Cost EMIs
The catch behind No-Cost EMIs

The catch behind No-Cost EMIs

DSIJ Intelligence Article rating: 5.0

EMI is something some people think of casually, while some consider it as a ticking bomb. However, what if you only need to pay the principal amount in installments? Read on to find out more on whether to opt for no cost EMIs or not.

Syngene reported 64 per cent PAT growth in Q2FY20
Syngene reported 64 per cent PAT growth in Q2FY20

Syngene reported 64 per cent PAT growth in Q2FY20

Amir Shaikh Article rating: 3.5

In the second quarter of FY20, Syngene reported 11 per cent growth in the  total income to Rs. 485.2 crore from Rs. 436.8 crore in corresponding quarter a year ago

A Flat Trading Day in Making
A Flat Trading Day in Making

A Flat Trading Day in Making

DSIJ Intelligence-3 Article rating: 5.0

The last trading session saw key benchmark indices snapping their six-day winning streak. The bears found some space to comeback among the rampaging bulls; however, their success seems to be limited in scope. The early indications from SGX Nifty suggest the index to open flat to positive, as it is trading at 11,618.50 levels.

RSS
First31803181318231833185318731883189Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR